How to Obtain AMA
PRA Category 1
Credit(s)™
- Read the provided journal article and slides.
- Listen to the
audio discussion.
- Login to your account.
- Complete the registration / evaluation form.
- Print your personalized
CME certificate.
Rheumatology
Online CME
Survey
|
|
|
Efficacy and Safety of Abatacept or Infliximab vs Placebo in ATTEST:
A Phase III, Multi-centre, Randomised, Double-blind, Placebo-controlled
Study in Patients With Rheumatoid Arthritis and an Inadequate
Response to Methotrexate
Publication: Schiff M, et al. Ann Rheum Dis. 2008;67:1096-1103.
|
| |
| Release Date: November 21, 2008 |
Expiration Date: November 21, 2009 |
| Estimated Time of Completion |
45 minutes |
| Description / Overview |
The purpose of this activity is to assess the relative efficacy and safety of abatacept and infliximab in a single, double-blind, randomized, placebo-controlled study. |
| Objectives |
At the conclusion of this activity, the participant will be able to:
- Outline the study design of ATTEST.
- Compare and contrast the effectiveness of abatacept and infliximab on disease activity, physical function, and quality of life.
- Describe the adverse events reported in the abatacept and infliximab groups.
|
| Target Audience |
This activity is directed to physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in RA. |
| Accreditation |
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2. |
| Activity Director |
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio |
| Author / Faculty |
Michael H. Schiff, MD |
| Faculty Disclosure |
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO |
|
| |
Consulting: |
Abbott Laboratories; Elan; Genentech, Inc.; Roche Laboratories, Inc. |
| |
| |
Teaching
and Speaking: |
Genentech, Inc. |
| |
| Michael H. Schiff, MD |
|
| |
Consulting: |
Bristol-Myers Squibb Company |
| |
| |
Board Membership: |
Bristol-Myers Squibb Company |
|
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:
Roche Laboratories, Inc.
This CME activity was produced by
The Cleveland Clinic Foundation
Center for Continuing Education and DIME.
CME Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.
|
